title: Morphological adaptation in adult short bowel syndrome undergoing intestinal rehabilitation.
abstract: OBJECTIVE
  To observe the adaptive changes of the intestinal mucosa in patients with short bowel syndrome (SBS) who received intestinal rehabilitation therapy and further evaluate the feasibility of the magnifying endoscopy for monitoring intestinal adaptation.
  
  
  METHODS
  Ten patients with SBS received growth hormone (GH) (0.05 mg/kg/day), oral glutamine (30 g/day), plus enteral nutrition (EN) for 4 weeks. Intestinal absorptive function, mucosal morphology, proliferating, and apoptotic status were investigated before and after treatment.
  
  
  RESULTS
  All patients completed the treatment. Intestinal absorptive function and villus height were significantly improved after treatment (p < .05). Furthermore, the proliferation levels of the small bowel were increased (p < .05). In addition, we also found that magnifying endoscopy can well describe the microscopic changes of intestinal mucosa.
  
  
  CONCLUSIONS
  Treatment with GH, glutamine, and EN has positive effect on intestinal mucosal morphologic adaptation in patients with SBS. Furthermore, magnifying endoscopy for monitoring intestinal adaptation is practicable and reliable.
authors: Department of Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.
authors: Mingxiao
authors: M
authors: Guo
authors: Yousheng
authors: Y
authors: Li
authors: Zhiming
authors: Z
authors: Wang
authors: Bo
authors: B
authors: Wu
authors: Jian
authors: J
authors: Wang
authors: Jieshou
authors: J
authors: Li
mesh_terms: D000222:Adaptation, Physiological; D000293:Adolescent; D000328:Adult; D017209:Apoptosis; D053148:Caspase 3 / Q000032:analysis; D002455:Cell Division; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D004750:Enteral Nutrition; D005260:Female; D005973:Glutamine / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007082:Ileum / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology; D007413:Intestinal Mucosa / Q000737:chemistry / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D007583:Jejunum / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008871:Microvilli / Q000648:ultrastructure; D008875:Middle Aged; D009584:Nitrogen / Q000032:analysis; D012778:Short Bowel Syndrome / Q000188:drug therapy / Q000473:pathology* / Q000534:rehabilitation / Q000628:therapy
chemical_list: D019394:Ki-67 Antigen; D005973:Glutamine; D019382:Human Growth Hormone; C505407:CASP3 protein, human; D053148:Caspase 3; D009584:Nitrogen